A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute Leukemia

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Leukemia
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Relapsed or refractory acute leukemia (ALL or AML) and has exhausted, or is ineligible for, available therapeutic options. 2) Acute leukemia harboring KMT2A (eg, gene rearrangement/translocation, partial tandem duplication,or wild-type amplification)or NPM1(eg,Exon 12 frameshift) alterations. 3) A woman of childbearing potential must have a negative highly sensitive serum ß-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment.

You may not be eligible for this study if the following are true:

  • 1) Acute promyelocytic leukemia. 2) Known CNS involvement. 3) Prior solid organ transplantation. 4) Cardiovascular disease that is uncontrolled or that was diagnosed within 6 months prior to the first dose of study treatment.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.